Cancer

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient...

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)...

A New Publication Highlights the Use of cResponse in the Assessment of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer

A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and...

Massive Bio Pioneers Clinical Trial Recruitment Innovation with Strategic Support from Evernorth Health, Inc.

Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven TechnologiesNEW YORK--(BUSINESS WIRE)--Massive Bio Inc., a trailblazing...

error: Content is protected !!